NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Subscribe To Our Newsletter & Stay Updated
